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Background: Glucagon-like peptide-1 (GLP-1) receptor agonists can maintain good glycemic control in some
diabetic. Here we compared the clinical characteristics and parameters reflecting glucose metabolism at the time
of the initiation of GLP-1 receptor agonist therapy between patients who responded well to therapy and those
who did not.
Methods: The records of 43 patients with type 2 diabetes who started receiving GLP-1 receptor agonist therapy
during hospitalization were retrospectively reviewed. Glucagon stimulation tests were performed, and patients were
started on liraglutide or exenatide therapy. Preprandial blood glucose levels were measured on days 2 and 3 of
GLP-1 receptor agonist therapy. We used the Cox proportional hazard model to compare clinical parameters between
responders (HbA1c level <8% at more than 3 months after the initiation of treatment) and non-responders (HbA1c
level ≥8% at more than 3 months after the initiation of treatment or a switch to insulin therapy at any time).
Results: Twenty-six of the 43 patients were classified as non-responders. At baseline, mean HbA1c levels were 9.9%
among responders and 9.7% among non-responders. Compared with treatment with only diet or metformin,
the hazard ratio [HR] for non-response was 5.3 (95% confidence interval [CI]: 1.16-24.6, P = 0.03) for insulin therapy
and 5.0 (95% CI: 1.13-22.16, P = 0.03) for sulfonylurea therapy. Compared with the lowest tertile, the HRs for
non-response in the highest tertile were 3.1 (95% CI: 1.04-8.97, P = 0.04) for the mean preprandial blood glucose level
on days 2 and 3 and 3.4 (95% CI: 1.05-11.01, P = 0.04) for the body mass index. The response was not significantly
associated with the duration of diabetes or the glucagon stimulation test results. A receiver operating curve analysis
showed that the mean preprandial blood glucose level had the highest area under the curve value (=0.72) for the
prediction of non-responders.
Conclusions: In patients with poorly controlled diabetes, the response to GLP-1 receptor agonist therapy was
significantly associated with the treatment used before the initiation of therapy, the body mass index, and the
mean preprandial blood glucose level during the 2 days after the initiation of therapy.
Keywords: Glycemic control, Glucagon-like peptide-1 agonist, Predictors of response, Preprandial blood glucose
level, Liraglutide, ExenatideBackground
In patients with diabetes, the maintenance of good glycemic
control is the most important method for preventing the
progression of diabetes-related complications. According to
the position statement of the European Association for
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tor agonists, such as liraglutide and exenatide, are recom-
mended because of their ability to maintain good glycemic
control in diabetic patients without resulting in weight gain
or significant hypoglycemia [1,2]. They have also been
shown to help maintain β-cell mass and function [3]. GLP-
1 receptor agonist therapy has not yet been widely used in
Japan [4]; however, it has recently begun to attract more
attention [5,6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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agonist therapy and some do not. For medical and
socio-economic reasons, it is important to determine
methods of predicting the response to GLP-1 receptor
agonists. In consideration of low risk of hypoglycemia
and lesser effect on body weight gain, previous studies
[7-9] have been switched from insulin therapy to GLP-1
receptor agonist therapy and certain number of the
patients have been regarded effective.
Previous studies [7-11] have reported that a short
history of diabetes, a high fasting serum C-peptide (CPR)
level, a high stimulated CPR level at 6 min during gluca-
gon stimulation (CPR6), and a high urinary C-peptide
level at the start of treatment may predict the response
to GLP-1 receptor agonist therapy in terms of reducing
the blood glucose levels. Combined GLP-1 receptor
agonist and insulin therapy has shown promising results
in patients who are modestly obese and have a longer dur-
ation of diabetes [12]. These studies have demonstrated
the importance of identifying predictors of response to
treatment; however, whether other factors, such as previ-
ous antidiabetic treatment and glucose levels soon after
the initiation of GLP-1 receptor agonist therapy, are cap-
able of predicting the response to GLP-1 receptor agonist
therapy remains uncertain.
Therefore, the present study investigated previous
antidiabetic treatment and the preprandial blood glucose
levels on days 2 and 3 of GLP-1 receptor agonist therapy
as well as clinical characteristics and parameters reflecting
glucose metabolism before the initiation of GLP-1 recep-
tor agonist therapy, including the change in the serum
CPR level during a glucagon stimulation test and the 24-h
urinary CPR excretion (U-CPR) level. These data were




We conducted a retrospective cohort study of patients
with type 2 diabetes who were admitted to the National
Center for Global Health and Medicine for the treatment
of hyperglycemia between September 2009 and December
2012 and who started receiving GLP-1 receptor agonist
therapy during their period of hospitalization. All the
patients initially received inpatient diet therapy (the
optimal caloric intake was calculated as the ideal body
weight × 25), exercise therapy, and multiple insulin injec-
tion therapy to maintain their preprandial blood glucose
levels at <200 mg/dL.
GLP-1 receptor agonist therapy was initiated after
a glucagon stimulation test, starting with liraglutide
(0.3 mg daily) or exenatide (5 μg twice daily). Insulin
therapy was discontinued at the time of the initiation
of GLP-1 receptor agonist therapy. A maximum oftwo oral hypoglycemic drugs were used at a time. The
maximum glimepiride dose was 2 mg daily. Since we
switched patients from insulin therapy to GLP-1 receptor
agonist therapy during hospitalization, we carefully moni-
tored the patients for glucose fluctuations.
After hospital discharge, the patients returned for follow-
up visits at least every 2 months. Follow-up blood tests
included liver and kidney function tests and measurements
of the serum lipid level, the fasting plasma glucose level,
and the HbA1c level. The medication doses were increased
to the maximum dose at the discretion of the attending
physician, and patients were cautioned about adverse
effects such as marked anorexia, nausea, or diarrhea. The
maximum dose of liraglutide was 0.9 mg/day in Japan,
while that of exenatide was 10 μg twice daily. The present
study was approved by the institutional review board of
the National Center for Global Health and Medicine,
and written informed consent was waived because of
the retrospective design. This study was implemented
in accordance with the provisions of the Declaration of
Helsinki.
The primary objective of this study was to compare
the clinical parameters at the time of the initiation of
GLP-1 receptor agonist therapy between patients who
had achieved an HbA1c level of <8% [1] at more than
3 months after the initiation of treatment (responders)
and those who had not achieved an HbA1c level of <8%
(non-responders). Non-responders also included patients
who were switched to insulin therapy at any time because
of insufficient glycemic control.
Laboratory evaluations
A glucagon stimulation test was conducted after an 8-h
fast. The serum CPR level was measured before glucagon
injection and 6 min after the injection of 1 mg of glucagon,
and the difference between these two levels was calculated
(ΔCPR) [13]. Urine was collected for 24 h and stored in
a refrigerator. The serum and urinary CPR levels were
measured using the electro-chemiluminescence method.
Fasting plasma glucose concentrations were measured
using the electrode method. HbA1c levels were measured
using high-pressure liquid chromatography. The HbA1c
values were recorded as Japan Diabetes Society (JDS)
values and were then converted to the National Glycohe-
moglobin Standardization Program (NGSP) values as
follows: HbA1c (NGSP) =1.02 ×HbA1c (JDS) +0.25% [14].
All the blood samples were assayed at a central laboratory.
The preprandial blood glucose levels were measured at
least 3 times a day using a self-monitoring blood glucose
device (One Touch® Ultra®; Johnson and Johnson, USA).
The blood glucose levels were measured before breakfast,
lunch, and dinner on days 2 and 3 of GLP-1 receptor agon-
ist therapy to determine whether the long-term response
could be predicted by these values.
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The objective of this study was to identify factors that
could predict the response to treatment at the time of
the initiation of GLP-1 receptor agonist therapy. The
non-response rate was analyzed using a time-to-event
survival analysis. The person-time of the follow-up was
calculated from the time of initiation of GLP-1 receptor
agonist treatment until the definitive event (i.e., the
achievement of an HbA1c level of ≥8% at more than
3 months after the initiation of treatment or a switch in
treatment to insulin therapy) or the end of the follow-up
period. The hazard ratios for the response to treatment
were calculated using the Cox proportional hazards
model. We selected the factors that were shown to be
significantly associated with the response to treatment
when evaluated using univariate Cox proportional hazards
analyses (P < 0.05) in addition to the body mass index
(BMI), the duration of diabetes, CPR6, and U-CPR, which
have been reported to be related to patient outcome. The
subjects were grouped into 3 groups (tertiles for con-
tinuous variables), and the long-term cumulative rate of
treatment failure for each group was estimated using
the Kaplan-Meier method. The assumption of proportional
hazards was assessed using Schoenfeld residuals (P > 0.05
for all the tests).
Various cutoff points were calculated using a receiver
operating characteristic (ROC) curve analysis of the area
under the curve (AUC), true positives, false positives,
true negatives, false negatives, sensitivity, and specificity
of potential predictors of the response to GLP-1 receptor
agonist therapy.
All the P values were two-tailed, and values less than
0.05 were considered significant. All the statistical ana-
lyses were performed using Stata statistical software
(version 12.1; Stata Corp., TX, USA).
Results
This study included 43 patients with a mean follow-up
period of 131 days (maximum follow-up, 585 days).
Twenty-six patients were classified as non-responders, of
which three discontinued GLP-1 receptor agonist therapy
within 3 months because of high blood glucose levels.
Table 1 shows a comparison of the baseline characteristics
of responders and non-responders using univariate Cox
proportional hazards analyses.
There were no significant differences in sex, age, type
of GLP-1 receptor agonist, or HbA1c level at the time
of initiation of treatment between responders and non-
responders. When a P level <0.05 was regarded as indi-
cating a significant difference between groups, previous
treatment other than diet or metformin was found to
be a potential predictor of a non-response to GLP-1
receptor agonist therapy (Table 1). Furthermore, the BMI,
duration of diabetes, and CPR6 and U-CPR levels weredivided into tertiles to evaluate the effects of long-term
factors on response, and the rate of treatment failure in
each tertile was estimated using the Kaplan-Meier method
(Figure 1).
Compared with treatment with only diet or metformin,
the hazard ratio for non-response was 5.3 (95% confidence
interval [CI] 1.16-24.6, P = 0.03) for insulin therapy and
5.0 (95% CI 1.13-22.16, P = 0.03) for sulfonylurea therapy
(Table 2). Compared with the lowest tertile for BMI, the
hazard ratio for non-response was 3.9 (95% CI 1.23-12.38,
P = 0.02) for the middle tertile and 3.4 (95% CI 1.05-11.01,
P = 0.04) for the highest tertile. There was no significant
difference in response among tertiles according to CPR6,
U-CPR, or the duration of diabetes. Compared with a
duration of diabetes of <5 years, the hazard ratio for
non-response was 4.1 (95% CI 0.97-17.67, P = 0.054) in
patients with a duration of diabetes of ≥5 years.
Blood glucose levels early after the initiation of GLP-1
receptor agonist therapy were analyzed using measure-
ments taken before 3 meals on both day 2 and day 3 of
therapy. There was no significant difference in the early-
morning fasting blood glucose level between responders
and non-responders. Significant differences in the mean
preprandial blood glucose levels were observed between
the responders and the non-responders, with a hazard
ratio of 1.01 per 1-mg/dL increase (95% CI, 1.00-1.02;
P = 0.03 for trend) for day 2, 1.01 per 1-mg/dL increase
(95% CI, 1.00-1.02; P = 0.04 for trend) for day 3, and
1.01 per 1-mg/dL increase (95% CI, 1.00-1.02; P = 0.03
for trend) for days 2 and 3 combined. The hazard ratio
of the mean preprandial blood glucose level for day 2
and 3 combined was 1.90 per 50-mg/dL increase (95% CI,
1.07-3.39; P = 0.03 for trend) and 3.61 per 100-mg/dL
increase (95% CI, 1.14-11.49; P = 0.03 for trend).
Compared with the lowest tertile for the mean pre-
prandial blood glucose level for days 2 and 3 combined,
the hazard ratio for the non-response group was 3.5 per
1-mg/dL increase (95% CI, 1.19-10.12; P =0.02 for trend)
for the middle tertile and 3.1 per 1-mg/dL increase (95%
CI, 1.04-8.97; P = 0.04 for trend) for the highest tertile.
The mean preprandial blood glucose level for days 2
and 3 combined was indicated by the ROC curve analysis
that had the highest AUC value (AUC = 0.72; Table 1).
The corresponding optimal cut-off point, at which the
sum of the sensitivity and the specificity reached a max-
imum, was 138 mg/dL. Diagnostic parameters, including
the sensitivity and specificity, depended strongly on the
chosen cutoff point (Table 3).
Discussion
The results of this study suggest that the treatment used
before the initiation of GLP-1 receptor agonist therapy
and the mean preprandial blood glucose level during the
2 days after the initiation of therapy predicted the long-
Table 1 Baseline characteristics of patients*
Responder Non-responder Hazard ratio P
value AUC(N =17) (N =26) (95% CI)
Male (%) 64.7 61.5 0.85 (0.39-1.89) 0.70 NA
Age (years) 57.1 ± 12.2 61.9 ± 16.1 1.01 (0.98-1.04) 0.63 0.62
Body mass index (kg/m2) † 29.1 ± 9.8 29.5 ± 5.5 1.04 (0.98-1.10) 0.21 0.66
Exenatide (%) 58.8 65.4 1.56 (0.67-3.63) 0.31 NA
Duration of diabetes (years) 10.6 ± 8.6 14.8 ± 10.6 1.04 (0.99-1.08) 0.051 0.62
Fasting C-peptide (ng/mL) 2.4 ± 1.5 2.2 ± 1.1 0.91 (0.60-1.38) 0.66 0.52
CPR6 (ng/mL)‡ 4.0 ± 2.5 4.4 ± 2.4 1.05 (0.87-1.27) 0.60 0.57
ΔCPR (ng/mL)§ 1.5 ± 1.1 2.1 ± 1.5 1.15 (0.90-1.47) 0.27 0.62
C-peptide index¶ 1.8 ± 1.2 1.4 ± 0.7 0.79 (0.46-1.34) 0.37 0.55
U-CPR (μg/day) 87.2 ± 47.7 91.0 ± 71.1 1.00 (0.99-1.01) 0.82 0.45
Preprandial glucose of the previous day GLP-1 initiated (mg/dL) 162.6 ± 50.4 174.2 ± 36.9 1.00 (0.99-1.01) 0.40 0.60
Average preprandial glucose level over 2 days after the
initiation of GLP-1 receptor agonist treatment (mg/dL)
140.0 ± 26.1 165.1 ± 31.8 1.01 (1.00-1.02) 0.03 0.72
HbA1c (%) 9.9 ± 1.8 9.7 ± 1.6 0.93 (0.74-1.16) 0.51 0.49
Previous antidiabetic treatment (%)
Diet and/or metformin 47.1 11.5 1.0 (Reference) NA
Sulfonylurea 23.5 38.5 5.0 (1.13-22.16) 0.03 NA
Insulin 29.4 50.0 5.3 (1.16-24.56) 0.03 NA
Dose of insulin (unit) 21.2 ± 5.9 26 ± 8.4 NA NA NA
*Values for responders and non-responders to treatment are shown as the percentage (number) or mean ± standard deviation. Hazard ratios for response to
treatment were analyzed using the Cox proportional hazards model. Areas under the receiver operating characteristic curve (AUC) were compared using a logistic
regression analysis.
†The body mass index is the weight in kilograms divided by the square of the height in meters.
‡Serum C-peptide level at 6 min during a glucagon stimulation test.
§Change in serum C-peptide level between baseline and 6 min during a glucagon stimulation test.
¶Fasting serum C-peptide level divided by fasting plasma glucose level.
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insulin and the duration of the diabetes history were not
useful predictors. Some patients with a higher BMI and
a higher CPR6 did not respond to GLP-1 receptor agon-
ist therapy.
Pancreatic β-cell function is reduced by 20% in patients
with glucose intolerance and 50% in patients with diabetes
[15]. GLP-1 receptor agonist therapy has been reported to
be more effective in patients with relatively high levels of
insulin secretion, as determined by the 24-h urinary CPR
excretion, the fasting serum CPR level, the CPR index [9],
and the CPR6 [10]. In this study, however, these markers
of insulin secretion were not predictors of the response to
GLP-1 receptor agonist therapy.
There are two possible explanations for these results.
First, our study included patients who could maintain
their insulin secretion levels to some extent, while previ-
ous studies included patients with a U-CPR of less than
20 μg/day, indicating severely impaired insulin secretion
[9]. The inclusion of patients treated with sulfonylureas
also likely contributed to the difference in results when
compared with those of a previous study [10]. Second,
glycemic control is affected by both the level of insulinsecretion and the degree of insulin resistance [16].
Patients with a higher BMI, which is correlated with an
increased CRP6 level (r = 0.68), tended not to respond
to GLP-1 receptor agonist therapy. This finding sug-
gested that the stimulation of insulin secretion by a
GLP-1 receptor agonist might be insufficient to lower
the blood glucose level when insulin resistance is
present. In this context, good glycemic control might
have been relatively achieved among the second tertile
of patients whose insulin secretion might have been
modestly preserved and who might not have had insulin
resistance.
Previous studies reported that liraglutide therapy is
more effective in patients with a shorter duration of
diabetes [8-10]. However, other studies have reported
that patients with long-term diabetes may achieve better
glycemic control with exenatide therapy [11]. Most of the
patients in our study had a long duration of diabetes.
Therefore, the duration of diabetes was not associated
with efficacy when the patients were divided into tertile
groups. Although the number of patients was relatively
small, patients with a ≥5-year history of diabetes were
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Figure 1 Kaplan-Meier estimates of the cumulative incidence of non-response to treatment, up to 600 days. (A) Previous antidiabetic
treatment, (B) BMI: body mass index, (C) Duration of diabetes, (D) U-CPR: 24-h urinary C-peptide excretion, (E) CPR6: stimulated C-peptide level at
6 min during glucagon stimulation, (F) Average preprandial glucose level over 2 days after the initiation of GLP-1 receptor agonist treatment,
GLP-1: Glucagon-like peptide-1.
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history.
It was previously reported that patients who had been
previously treated with diet and exercise achieved a greater
reduction in their HbA1c levels with GLP-1 receptor
agonist therapy than patients who had previously received
other treatments [17]. Patients who had been previously
treated with monotherapy, particularly metformin, were
also reported to achieve better glycemic control with
GLP-1 receptor agonist therapy than patients who had
been previously treated with multiple oral hypoglycemic
agents [18]. These findings are consistent with guidelines
recommending the use of GLP-1 receptor agonists as
second-line therapeutic agents [1] and are also consistent
with our results.
Most of the patients included in the present study
exhibited sustained postbreakfast hyperglycemia before
the introduction of GLP-1 therapy [19]. A glycemic controlof HbA1c <8.0% could be achieved only when the blood
glucose levels before lunch and before dinner as well as
those before breakfast were lowered [20,21]. Accord-
ingly, we evaluated the predictive ability of the mean
preprandial blood glucose level during the 2 days after
the initiation of GLP-1 receptor agonist therapy. Of
note, the effectiveness of the reduction in the glucose
level in response to GLP-1 receptor agonist therapy
after the initiation of therapy was preserved and pos-
sessed the ability to predict a long-term improvement
in glycemic control. Evaluations using blood glucose
measurements performed soon after the introduction of
GLP-1 receptor agonist therapy might also possess the
ability to predict the achievement of more strict gly-
cemic control, such as HbA1c <7.0%. For this purpose,
more precise measurements of blood glucose, including
postprandial glucose levels [22] and continuous glucose
monitoring [23], might be beneficial.
Table 2 Hazard ratios for non-response to treatment
N Median (Range) Hazard ratio (95% CI) P value
BMI (kg/m2) 43 26.31 (19.8-52.6)
Tertile 1 (lowest) 14 23.6 (19.8-25.0) 1.0 (Reference)
Tertile 2 14 26.3 (25.1-30.3) 3.9 (1.24-12.37) 0.02
Tertile 3 (highest) 15 33.2 (30.4-52.6) 3.4 (1.04-11.01) 0.04
Duration of diabetes (years) 43 11 (0.1-38)
Tertile 1 (lowest) 15 4 (0.1-6) 1.0 (Reference)
Tertile 2 15 12 (8-17) 1.7 (0.67-4.4) 0.25
Tertile 3 (highest) 13 23 (18-38) 1.7 (0.63-4.5) 0.30
CPR6 (ng/mL) 43 3.9 (0.5-11.0)
Tertile 1 (lowest) 15 2.0 (0.5-2.7) 1.0 (Reference)
Tertile 2 14 4.0 (2.8-4.9) 0.4 (0.13-1.01) 0.054
Tertile 3 (highest) 14 6.7 (5.3-11.0) 1.3 (0.51-3.28) 0.59
U-CPR (μg/day) 43 71.6 (16.0-249.8)
Tertile 1 (lowest) 15 33.7 (16.0-49.7) 1.0 (Reference)
Tertile 2 14 73.7 (50.8-112.8) 0.4 (0.16-1.18) 0.10
Tertile 3 (highest) 14 160.0 (121.7-249.8) 0.6 (0.23-1.34) 0.19
Average preprandial glucose level over 2 days after the
initiation of GLP-1 receptor agonist treatment (mg/dL)
43 149.3 (99.8-246.2)
Tertile 1 (lowest) 15 130.3 (99.8-137.7) 1.0 (Reference)
Tertile 2 14 149.7 (140.2-161.0) 3.5 (1.19-10.12) 0.02
Tertile 3 (highest) 14 188.7 (161.5-246.2) 3.1 (1.04-8.97) 0.04
Previous antidiabetic treatment 43
Diet and/or metformin 11 1.0 (Reference)
Sulfonylurea 14 5.0 (1.13-22.16) 0.03
Insulin 18 5.3 (1.16-24.56) 0.03
Abbreviations: CI confidence interval, BMI body mass index, GLP-1 Glucagon-like peptide-1, CPR C-peptide, CPR6 stimulated C-peptide level at 6 min during glucagon
stimulation, U-CPR 24-h urinary C-peptide excretion.
Table 3 Diagnostic measures at various cutoff points for the prediction of non-response to treatment
Predictors, Cutoff point TP/FP TN/FN Sensitivity Specificity
Average preprandial glucose level over 2 days after the
initiation of GLP-1 receptor agonist treatment (mg/dL)
<120 26/12 5/0 100 29.4
<130 25/11 6/1 96.2 35.3
<140 21/7 10/5 80.8 58.8
<150 15/6 11/11 57.7 64.7
<160 10/5 12/16 38.5 70.6
<170 9/3 14/17 34.6 82.4
<180 8/1 16/18 30.8 94.1
<190 6/0 17/20 23.1 100.0
<200 4/0 17/22 15.4 100.0
Abbreviations: TP number of true positives, FP number of false positives, TN number of true negatives, FN number of false negatives, GLP-1 Glucagon-like peptide-1.
Imai et al. Diabetology & Metabolic Syndrome 2014, 6:110 Page 6 of 8
http://www.dmsjournal.com/content/6/1/110
Imai et al. Diabetology & Metabolic Syndrome 2014, 6:110 Page 7 of 8
http://www.dmsjournal.com/content/6/1/110Limitations
First, this was an observational study with a small sample
size, leading to wide confidence intervals for our estimates.
Second, the tertile analysis may have reduced the statistical
power, since it discards within-category information, espe-
cially in studies with small sample sizes. However, this
analysis avoids making the assumption of a linear relation.
Third, the study population consisted of patients who
began receiving GLP-1 receptor agonist therapy during
hospitalization for the treatment of hyperglycemia. Both
of the mean HbA1c for responders (9.9%) and non-
responders (9.7%) were high. Therefore, the subjects are
not representative of the general type 2 diabetic popula-
tion. Fourth, for patients who were already introduced
insulin therapy, switching to GLP-1 receptor agonist
therapy is less common. Fifth, the discontinuation of
GLP-1 receptor agonist therapy was performed at the
discretion of the attending physician, and there were no
clearly defined criteria for discontinuation. Finally, in
this study, we could not perform separate analyses
according to the use of liraglutide or exenatide because
of the small number of samples. Therefore, a prospective
clinical study with a stricter protocol and a larger number
of patients utilizing each formulation is necessary to fur-
ther evaluate the effectiveness of GLP-1 receptor agonist
therapy.
Conclusions
In patients with poorly controlled diabetes, our findings
suggest that patients who have received previous treat-
ments for diabetes other than diet and exercise or metfor-
min, who have a high BMI, and who have a high mean
preprandial blood glucose level do not tend to respond well
to GLP-1 receptor agonist therapy.
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